Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec 17;20(24):6352.
doi: 10.3390/ijms20246352.

Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers"

Affiliations
Editorial

Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers"

Buddhadev Layek et al. Int J Mol Sci. .

Abstract

Safe and effective delivery of therapeutics at the target site is the key to successful therapy. Nanocarriers can offer significant advantages over conventional dosage forms. Over the decades, nanoparticles have been extensively used to increase bioavailability, improve solubility and stability, reduce toxicities, and facilitate the controlled release of therapeutics. Further, nanoparticles have often been surface-functionalized with a variety of ligands to enhance circulation half-life and increase target-specificity. Although nanotechnology has shown significant therapeutic benefits for multiple biomedical applications, limited nanoparticle-based formulations have progressed to clinical trials, and only a few have reached the pharmaceutical market. This editorial is an introduction to the special issue entitled Surface-Functionalized Nanoparticles as Drug Carriers. We outline the scope of the special issue, summarize the results and conclusions of the nine articles published in this issue, and provide perspective on the application of surface-functionalized nanoparticles in the drug delivery field.

Keywords: bioavailability; controlled release; drug delivery; nanoparticles; surface-functionalized nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Din F.U., Aman W., Ullah I., Qureshi O.S., Mustapha O., Shafique S., Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 2017;12:7291–7309. doi: 10.2147/IJN.S146315. - DOI - PMC - PubMed
    1. How C.W., Rasedee A., Manickam S., Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity. Colloids Surf. B: Biointerfaces. 2013;112:393–399. doi: 10.1016/j.colsurfb.2013.08.009. - DOI - PubMed
    1. Mishra B., Patel B.B., Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine. 2010;6:9–24. doi: 10.1016/j.nano.2009.04.008. - DOI - PubMed
    1. Layek B., Lipp L., Singh J. Apc targeted micelle for enhanced intradermal delivery of hepatitis b DNA vaccine. J. Control. Release. 2015;207:143–153. doi: 10.1016/j.jconrel.2015.04.014. - DOI - PubMed
    1. Teng C., Chai Z., Yuan Z., Ren L., Lin C., Yan Z., He W., Qin C., Yang L., Han X., et al. Desirable pegylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and cd44 receptor-mediated tumor targeting. Nanomed. Nanotechnol. Biol. Med. 2020;24:102105. doi: 10.1016/j.nano.2019.102105. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources